CEBPA and neoplasm: Treatment of subcutaneous pancreatic mouse tumor model or the advanced liver-metastatic pancreatic cancer model with the CEBPA-saRNA aptamer conjugate resulted in a significant reduction in tumor growth, mediated by the increase of p21 gene which is downstream of CEBPA transcriptional activation [50,51].